Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $5.55 $4,500 - $8,325
1,500 Added 3.77%
41,300 $135,000
Q2 2024

Aug 15, 2024

SELL
$3.31 - $18.51 $193,966 - $1.08 Million
-58,600 Reduced 59.55%
39,800 $169,000
Q1 2024

May 07, 2024

BUY
$9.77 - $21.47 $774,761 - $1.7 Million
79,300 Added 415.18%
98,400 $1.45 Million
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $11,648 - $26,286
2,600 Added 15.76%
19,100 $183,000
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $73,920 - $102,135
16,500 New
16,500 $76,000
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $31,905 - $55,332
10,600 New
10,600 $37,000
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $119,325 - $164,100
7,500 Added 75.76%
17,400 $279,000
Q3 2021

Nov 15, 2021

SELL
$19.74 - $28.7 $665,238 - $967,190
-33,700 Reduced 77.29%
9,900 $207,000
Q2 2021

Aug 11, 2021

SELL
$20.49 - $35.63 $471,269 - $819,490
-23,000 Reduced 34.53%
43,600 $1.17 Million
Q1 2021

May 17, 2021

BUY
$18.99 - $33.2 $311,436 - $544,480
16,400 Added 32.67%
66,600 $2.12 Million
Q3 2020

Nov 16, 2020

SELL
$24.69 - $31.6 $1.62 Million - $2.08 Million
-65,800 Reduced 56.72%
50,200 $1.27 Million
Q2 2020

Aug 14, 2020

BUY
$5.2 - $29.12 $349,960 - $1.96 Million
67,300 Added 138.19%
116,000 $3.24 Million
Q4 2019

Feb 14, 2020

SELL
$7.95 - $12.27 $60,420 - $93,252
-7,600 Reduced 13.5%
48,700 $530,000
Q3 2019

Nov 14, 2019

SELL
$12.44 - $17.48 $501,332 - $704,444
-40,300 Reduced 41.72%
56,300 $718,000
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $333,730 - $453,330
23,000 Added 31.25%
96,600 $1.64 Million
Q1 2019

May 15, 2019

BUY
$11.11 - $25.6 $134,431 - $309,760
12,100 Added 19.67%
73,600 $1.32 Million
Q4 2017

Feb 14, 2018

BUY
$16.19 - $20.3 $351,323 - $440,510
21,700 Added 54.52%
61,500 $1.17 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $617,696 - $753,812
39,800
39,800 $736,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $219M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.